ABC Heart Fail Cardiomyop 2022; 2(1): 55-63
Essential Therapy for Heart Failure with Preserved Ejection Fraction in 2022
Luiz Cláudio Danzmann
, Joana Carolina Junqueira de Brum, Leticia Kunst, Priscila Braun, Eduardo Lima Garcia
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a syndrome in which there is clinical evidence of heart failure (HF), left ventricle ejection fraction (LVEF) ≥50%, and evidence of diastolic dysfunction and/or structural cardiac changes. The pathophysiology of HF with preserved LVEF is related to the primary morbidities responsible for cardiac and vascular aggression via a chronic proinflammatory state involving the endothelium. Currently, the foundation of management of HFpEF rests on 5 pillars: control of circulatory congestion, management of primary morbidities or etiologies, use of medications with proven clinical benefit, identification and management of secondary etiologies, and cardiopulmonary rehabilitation. Essential therapy for HFpEF is founded on precise diagnosis, definition of etiology, estimation of severity, and use of medications with cardiovascular action of proven efficacy.
Keywords: Functional Residual Capacity; Heart Failure; Stroke Volume
2,322
